Charles River Laboratories International, Inc. (CRL) Earnings Call Analysis

NYSE · Healthcare · Diagnostics & Research

Earnings Reports

• Charles River Laboratories (CRL) Q1 2026: Margin Expansion Path Drives 500 Basis Point 2H Rebound
  May 07, 2026
• Charles River Laboratories (CRL) Q4 2025: DSA Bookings Jump to 1.12x as Biotech Funding Rebounds
  February 24, 2026
• Charles River Laboratories (CRL) Q3 2025: 7% Portfolio Divestiture Targets $0.30 EPS Accretion
  November 05, 2025
• Charles River (CRL) Q2 2025: DSA Net Book-to-Bill Climbs to 0.93, Signaling Demand Stabilization Path
  August 06, 2025
• Charles River Laboratories (CRL) Q1 2025: DSA Bookings Surge 20%, Signaling Demand Stabilization Amid Regulatory Shift
  July 06, 2025

Browse all companies